Response to Letter to the Editor: "Failure Rate of Antitumor Necrosis Factor Alpha Biologics in Very Early Onset Inflammatory Bowel Disease"
Inflamm Bowel Dis
.
2024 Mar 1;30(3):513-514.
doi: 10.1093/ibd/izad317.
Authors
Lauren V Collen
1
,
Scott B Snapper
1
Affiliation
1
Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
PMID:
38206353
PMCID:
PMC10906351
(available on
2025-01-11
)
DOI:
10.1093/ibd/izad317
No abstract available
Publication types
Editorial
Comment
MeSH terms
Biological Products* / therapeutic use
Humans
Inflammatory Bowel Diseases* / drug therapy
Necrosis
Tumor Necrosis Factor-alpha
Substances
Biological Products
Tumor Necrosis Factor-alpha
Grants and funding
RC2DK122532/NH/NIH HHS/United States
RC2DK122532/NH/NIH HHS/United States
DK/NIDDK NIH HHS/United States